Venetoclax and Decitabine in R/R T-ALL
The goal of this phase 2 clinical trial is to test the efficacy of decitabine and venetoclax combination chemotherapy in relapsed or refractory adult T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

This study use a modified regimen of decitabine and venetoclax.
T Lymphoblastic Leukemia/Lymphoma
DRUG: decitabine plus venetoclax
The rate of composite Complete remission, CR: complete remission CRh: complete remission with partial hematologic recovery CRi: complete remission with incomplete hematologic recovery MLFS: morphologic leukemia-free state, 1 year
Composite overall response rate, cORR: CR/CRh/CRi/MLFS+PR, 1 year|Clinical benefit rate, CR: complete remission CRh: complete remission with partial hematologic recovery CRi: complete remission with incomplete hematologic recovery MLFS: morphologic leukemia-free state PR: partial remission stable disease, 1 year|Duration of response, by months, 1 year|Bridging to allogeneic hematopoietic stem cell transplantation (HSCT), by rate, 1 year|Progression-free survival (PFS), by months, 1 year|Overall survival (OS), by months, 1 year
Our study is conducted in collaboration with Korean adult acute lymphoblastic leukemia working party (KALLWP) and consortium for improving survival of lymphoma (CISL). This study recruits adult patients with R/R T-ALL/LBL and treated with 7-day decitabine plus 3 weeks of venetoclax up to 12 cycles.